Table 4 Baseline demographic and clinical characteristics of responders and non-responders in the three trials
ALLEGRO | BRAVO | CONCERTO | ||||
|---|---|---|---|---|---|---|
NR N = 426 | R N = 675 | NR N = 367 | R N = 514 | NR N = 1015 | R N = 441 | |
Mean age (SD), years | 37.1 (8.5) | 39.7 (9.4) | 36.6 (8.8) | 37.8 (9.8) | 36.0 (8.8) | 37.3 (9.7) |
Gender, males (%) | 299 (70.2) | 46 (6.8) | 260 (70.8) | 20 (3.9) | 465 (45.8) | 0 (0.0) |
Mean number of relapses in the previous year (SD) | 1.60 (0.80) | 1.03 (0.49) | 1.55 (0.75) | 1.13 (0.45) | 1.44 (0.61) | 1.04 (0.20) |
Mean disease duration (SD), years | 8.22 (6.66) | 8.89 (6.87) | 6.62 (5.94) | 6.92 (6.53) | 5.94 (4.23) | 5.51 (3.66) |
Median EDSS (range) | 2.5 (0–5.5) | 2.5 (0–6) | 3 (0–5.5) | 2.5 (0–5.5) | 2.5 (0–5.5) | 2.5 (0–5.5) |
Number of patients with Gd+ baseline scans (%) | 159 (37.3) | 316 (46.8) | 123 (33.5) | 197 (38.3) | 352 (34.7) | 226 (51.3) |
Mean T2 lesion volume (SD), log-transformed cm3 | 1.97 (1.16) | 1.53 (1.29) | 1.72 (1.35) | 1.29 (1.45) | 1.68 (1.22) | 1.41 (1.19) |
Mean T1 lesion volume (SD), log-transformed cm3 | 0.31 (1.80) | −0.33 (1.96) | 0.42 (1.76) | − 0.27 (1.90) | 1.31 (1.31) | 0.97 (1.29) |
Mean normalized brain volume (SD), cm3 | 1553.9 (90.5) | 1599.5 (90.6) | 1547.5 (91.8) | 1610 (87.4) | 1410.4 (91.5) | 1491.7 (68.1) |